CSF2 and cancer: The immunotherapeutic potential of GM-CSF has been tested in a variety of modalities, including as a monotherapy, in combination with immune checkpoint blockade or as an adjuvant in GM-CSF-secreting allogenic cancer cell vaccines, with varied results [206].